Header Logo

Naoko Takebe

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentMedicine-SCC Shared Faculty
AddressSOCC 1
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zauderer MG, Jegede O, Jackman DM, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327. PMID: 39693587.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Jubashi A, Kotani D, Kojima T, Takebe N, Shitara K. Current landscape of targeted therapy in esophageal squamous cell carcinoma. Curr Probl Cancer. 2024 Dec; 53:101152. PMID: 39454516.
      Citations:    Fields:    Translation:Humans
    3. Macy ME, Mody R, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Williams PM, Patton DR, Coffey BD, Roy-Chowdhuri S, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418. PMID: 39298716; PMCID: PMC11488755.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Laetsch TW, Ludwig K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Mhlanga J, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258. PMID: 39298693; PMCID: PMC11581706.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S, Roper N, Reinhold WC, Robey RW, Takebe N, Gottesman MM, Thomas CJ, Boeva V, Berruti A, Abate A, Tamburello M, Sigala S, Hantel C, Weigand I, Wierman ME, Kiseljak-Vassiliades K, Del Rivero J, Pommier Y. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398. PMID: 39162009; PMCID: PMC11389377.
      Citations:    Fields:    Translation:HumansAnimalsCells
    6. Nelson MV, Kim A, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093. PMID: 38873934; PMCID: PMC11299954.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Ahluwalia MS, Ozair A, Drappatz J, Ye X, Peng S, Lee M, Rath S, Dhruv H, Hao Y, Berens ME, Walbert T, Holdhoff M, Lesser GJ, Cloughesy TF, Sloan AE, Takebe N, Couce M, Peereboom DM, Nabors B, Wen PY, Grossman SA, Rogers LR. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clin Cancer Res. 2024 Aug 01; 30(15):3167-3178. PMID: 38836759; PMCID: PMC11293959.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    8. Mizunuma M, Redon CE, Saha LK, Tran AD, Dhall A, Sebastian R, Taniyama D, Kruhlak MJ, Reinhold WC, Takebe N, Pommier Y. Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer Res Commun. 2024 08 01; 4(8):2101-2111. PMID: 39041239; PMCID: PMC11322923.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. Salkeni MA, Shin S, Takebe N, Stevens S, Chen A. Advanced Granulosa Cell Tumors of the Ovary: A Review with a Focus on Current and Novel Therapeutic Approaches. J Immunother Precis Oncol. 2024 Nov; 7(4):263-271. PMID: 39524463; PMCID: PMC11541922.
      Citations:    
    10. Glade Bender JL, Pinkney K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952. PMID: 38815151; PMCID: PMC11224971.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    11. Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, Puri S, Naqash AR. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024 Aug; 21(8):610-627. PMID: 38965396.
      Citations: 5     Fields:    Translation:Humans
    12. Jo U, Arakawa Y, Zimmermann A, Taniyama D, Mizunuma M, Jenkins LM, Maity T, Kumar S, Zenke FT, Takebe N, Pommier Y. The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Mol Cancer Ther. 2024 Jul 02; 23(7):911-923. PMID: 38466804; PMCID: PMC11555614.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    13. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801. PMID: 38920407; PMCID: PMC11264598.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    14. Vo KT, Sabnis AJ, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103. PMID: 38935895; PMCID: PMC11639582.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    15. Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen H, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749. PMID: 38456660; PMCID: PMC11061595.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    16. Arakawa Y, Jo U, Kumar S, Sun NY, Elloumi F, Thomas A, Roper N, Varghese DG, Takebe N, Zhang X, Ceribelli M, Holland DO, Beck E, Itkin Z, McKnight C, Wilson KM, Travers J, Klumpp-Thomas C, Thomas CJ, Hoang CD, Hernandez JM, Del Rivero J, Pommier Y. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. Cancer Res Commun. 2024 03 19; 4(3):834-848. PMID: 38451783; PMCID: PMC10949913.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    17. Dunn A, Takebe N, Chen A, Kummar S, Piekarz R, Kiesel B, Moore N, Doroshow J, Beumer JH, Gobburu JVS. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. Cancer Chemother Pharmacol. 2024 Aug; 94(2):157-167. PMID: 38483557; PMCID: PMC11390298.
      Citations:    Fields:    Translation:Humans
    18. Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Feb; 8:e2300371. PMID: 38330261; PMCID: PMC10860998.
      Citations:    Fields:    Translation:Humans
    19. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135. PMID: 38270822.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    20. Farooq M, Leevan E, Ahmed J, Ko B, Shin S, De Souza A, Takebe N. Blood-based multi-cancer detection: A state-of-the-art update. Curr Probl Cancer. 2024 02; 48:101059. PMID: 38181630.
      Citations: 2     Fields:    Translation:Humans
    21. Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga JC, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363. PMID: 37228094; PMCID: PMC11009504.
      Citations: 18     Fields:    Translation:Humans
    22. Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 07; 389(10):911-921. PMID: 37672694; PMCID: PMC10729808.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    23. O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023 Jun; 29(6):1349-1357. PMID: 37322121; PMCID: PMC10612141.
      Citations: 28     Fields:    Translation:Humans
    24. Ko B, Takebe N, Andrews O, Makena MR, Chen AP. Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells. 2023 05 05; 12(9). PMID: 37174716; PMCID: PMC10177415.
      Citations: 7     Fields:    Translation:Humans
    25. Nguyen J, Takebe N, Kummar S, Razak A, Chawla SP, George S, Patel SR, Keohan ML, Movva S, O'Sullivan Coyne G, Do K, Juwara L, Augustine B, Steinberg SM, Kuhlmann L, Ivy SP, Doroshow JH, Chen AP. Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res. 2023 04 03; 29(7):1200-1208. PMID: 36302173; PMCID: PMC10068440.
      Citations: 3     Fields:    Translation:Humans
    26. Sloan AE, Nock CJ, Ye X, Buerki R, Chang S, Lesser G, Norden A, Cloughesy T, Olson J, Kerstetter-Fogle A, Rich J, Fisher J, Desideri S, Takebe N, Timmer W, Grossman S, Prados M. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2023 Jan; 161(1):33-43. PMID: 36581779; PMCID: PMC11197851.
      Citations: 5     Fields:    Translation:HumansCells
    27. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840; PMCID: PMC10489509.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    28. Chihara D, Lin R, Flowers CR, Finnigan SR, Cordes LM, Fukuda Y, Huang EP, Rubinstein LV, Nastoupil LJ, Ivy SP, Doroshow JH, Takebe N. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521. PMID: 35964611; PMCID: PMC9477645.
      Citations: 10     Fields:    Translation:Humans
    29. Murai Y, Jo U, Arakawa Y, Takebe N, Pommier Y. SLFN11's surveillance role in protein homeostasis. Oncoscience. 2022; 9:35-37. PMID: 35903760; PMCID: PMC9313520.
      Citations:    
    30. Koubek EJ, Ralya AT, Larson TR, McGovern RM, Buhrow SA, Covey JM, Adjei AA, Takebe N, Ames MM, Goetz MP, Reid JM. Population Pharmacokinetics of Z-Endoxifen?in Patients With Advanced Solid Tumors. J Clin Pharmacol. 2022 09; 62(9):1121-1131. PMID: 35358345; PMCID: PMC9339467.
      Citations:    Fields:    Translation:Humans
    31. Gounder MM, Rosenbaum E, Wu N, Dickson MA, Sheikh TN, D'Angelo SP, Chi P, Keohan ML, Erinjeri JP, Antonescu CR, Agaram N, Hameed MR, Martindale M, Lefkowitz RA, Crago AM, Singer S, Tap WD, Takebe N, Qin LX, Schwartz GK. A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. Clin Cancer Res. 2022 04 14; 28(8):1586-1594. PMID: 35110418; PMCID: PMC9187109.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    32. Eckstein OS, Allen CE, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga J, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245. PMID: 35363510; PMCID: PMC9273373.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    33. Parsons DW, Janeway KA, Patton DR, Winter CL, Coffey B, Williams PM, Roy-Chowdhuri S, Tsongalis GJ, Routbort M, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Seibel NL, NCI-COG Pediatric MATCH Team. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234. PMID: 35353553; PMCID: PMC9273376.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    34. Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol. 2022 06 10; 40(17):1949-1957. PMID: 35263120; PMCID: PMC9177250.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    35. Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022 Mar 01; 6(1):13. PMID: 35233056; PMCID: PMC8888601.
      Citations: 11     
    36. Nakano H, Miyamoto T, Janjigian YY, Mine S, Mitsuya H, Ueno NT, Sharon E, Sakai S, Timmer WC, Nakabo S, Ikeuchi T, Fujiwara S, Kinjo M, Inuzuka T, Kume H, Shirai K, Yamaguchi N, Takabe K, Takebe N. Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World J Oncol. 2021 Dec; 12(6):183-194. PMID: 35059078; PMCID: PMC8734503.
      Citations: 2     
    37. O'Sullivan Coyne G, Kummar S, Hu J, Ganjoo K, Chow WA, Do KT, Zlott J, Bruns A, Rubinstein L, Foster JC, Juwara L, Meehan R, Piekarz R, Streicher H, Sharon E, Takebe N, Voth AR, Bottaro D, Costello R, Wright JJ, Doroshow JH, Chen AP. Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. Clin Cancer Res. 2022 01 15; 28(2):279-288. PMID: 34716194; PMCID: PMC8776602.
      Citations: 8     Fields:    Translation:Humans
    38. Murai Y, Jo U, Murai J, Fukuda S, Takebe N, Pommier Y. Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. iScience. 2021 Oct 22; 24(10):103173. PMID: 34693224; PMCID: PMC8517841.
      Citations: 4     
    39. Jo U, Murai Y, Takebe N, Thomas A, Pommier Y. Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers (Basel). 2021 Sep 14; 13(18). PMID: 34572827; PMCID: PMC8465591.
      Citations: 21     
    40. Cerna D, Lim B, Adelabu Y, Yoo S, Carter D, Fahim A, Mitsuuchi Y, Teicher BA, Bernhard E, Coleman CN, Takebe N, Ahmed MM. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme. Radiat Res. 2021 06 01; 195(6):549-560. PMID: 33826739.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    41. Fairchild CK, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers (Basel). 2021 May 12; 13(10). PMID: 34065859; PMCID: PMC8150384.
      Citations: 6     
    42. Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker D, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844. PMID: 33863809.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    43. Murai Y, Jo U, Murai J, Jenkins LM, Huang SN, Chakka S, Chen L, Cheng K, Fukuda S, Takebe N, Pommier Y. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Res. 2021 06 01; 81(11):3067-3078. PMID: 33863777; PMCID: PMC8178208.
      Citations: 16     Fields:    Translation:HumansCells
    44. Takebe N, Coyne GO, Kummar S, Collins J, Reid JM, Piekarz R, Moore N, Juwara L, Johnson BC, Bishop R, Lin FI, Mena E, Choyke PL, Lindenberg ML, Rubinstein LV, Bonilla CM, Goetz MP, Ames MM, McGovern RM, Streicher H, Covey JM, Doroshow JH, Chen AP. Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. Oncotarget. 2021 Feb 16; 12(4):268-277. PMID: 33659039; PMCID: PMC7899551.
      Citations: 5     Fields:    
    45. Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37. PMID: 32339229; PMCID: PMC7781457.
      Citations: 10     Fields:    Translation:HumansCells
    46. Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, J?nne PA, Oxnard GR. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611. PMID: 33376097; PMCID: PMC7976451.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    47. Mittra A, Takebe N, Florou V, Chen AP, Naqash AR. The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Hum Vaccin Immunother. 2021 07 03; 17(7):1935-1939. PMID: 33325769.
      Citations: 7     Fields:    Translation:Humans
    48. Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Pi?eyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7. PMID: 33217343; PMCID: PMC8478080.
      Citations: 40     Fields:    Translation:Humans
    49. Coyne GO, Kummar S, Meehan RS, Do K, Collins JM, Anderson L, Ishii K, Takebe N, Zlott J, Juwara L, Piekarz R, Streicher H, Sharon E, Rubinstein L, Voth AR, Lozier J, Dull AB, Wilsker D, Hinoue T, Laird PW, Ferry-Galow KV, Kinders RJ, Parchment RE, Doroshow JH, Chen AP. Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget. 2020 Nov 03; 11(44):3959-3971. PMID: 33216844; PMCID: PMC7646836.
      Citations: 7     Fields:    
    50. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA, NCI-MATCH team. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894. PMID: 33048619; PMCID: PMC7676882.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    51. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, NCI-MATCH Team. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029. PMID: 31922567; PMCID: PMC7566320.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    52. Fujiwara Y, Mittra A, Naqash AR, Takebe N. A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. Cancer Drug Resist. 2020; 3(3):252-275. PMID: 35582437.
      Citations: 22     
    53. Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020 04; 17(4):204-232. PMID: 31792354.
      Citations: 329     Fields:    Translation:HumansCells
    54. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511. PMID: 31271459; PMCID: PMC6848909.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    55. Stein MN, Goodin S, Gounder M, Gibbon D, Moss R, Portal D, Lindquist D, Zhao Y, Takebe N, Tan A, Aisner J, Lin H, Ready N, Mehnert JM. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020 06; 38(3):855-865. PMID: 31388792.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    56. Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers (Basel). 2019 Jul 31; 11(8). PMID: 31370269; PMCID: PMC6721450.
      Citations: 31     
    57. Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. Cancer J. 2019 Jul/Aug; 25(4):296-299. PMID: 31335394.
      Citations: 2     Fields:    Translation:Humans
    58. Kishimoto S, Oshima N, Rinker M, Krishna MC, Takebe N. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119. PMID: 31132741; PMCID: PMC8170839.
      Citations: 6     Fields:    Translation:Humans
    59. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 10; 106(4):803-809. PMID: 30927439.
      Citations: 2     Fields:    Translation:Humans
    60. Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361. PMID: 29928062; PMCID: PMC6013203.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    61. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882. PMID: 29467936; PMCID: PMC5805522.
      Citations: 4     Fields:    
    62. Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214. PMID: 29114963; PMCID: PMC5765308.
      Citations: 4     Fields:    Translation:Humans
    63. Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450. PMID: 28990119; PMCID: PMC5891394.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    64. Lih CJ, Takebe N. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017 May - Jun; 41(3):201-211. PMID: 28625332.
      Citations: 10     Fields:    Translation:Humans
    65. Miura K, Shima H, Takebe N, Rhie J, Satoh K, Kakugawa Y, Satoh M, Kinouchi M, Yamamoto K, Hasegawa Y, Kawai M, Kanazawa K, Fujiya T, Unno M, Katakura R. Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017 12; 14(12):1355-1366. PMID: 28379040.
      Citations: 5     Fields:    Translation:Humans
    66. Coyne GO, Takebe N, Chen AP. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193. PMID: 28372823.
      Citations: 39     Fields:    Translation:Humans
    67. Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200. PMID: 28343740.
      Citations: 22     Fields:    Translation:Humans
    68. Takebe N, Yap TA. Precision medicine in oncology. Curr Probl Cancer. 2017 May - Jun; 41(3):163-165. PMID: 28372822.
      Citations: 2     Fields:    Translation:Humans
    69. Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv. 2016 Dec 27; 1(3):250-259. PMID: 29046900; PMCID: PMC5642915.
      Citations: 53     Fields:    
    70. D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980. PMID: 28007774; PMCID: PMC5486863.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    71. Yonemori K, Hirakawa A, Kawachi A, Kinoshita F, Okuma H, Nishikawa T, Tamura K, Fujiwara Y, Takebe N. Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836. PMID: 27685762; PMCID: PMC5198943.
      Citations: 8     Fields:    Translation:Humans
    72. Bando H, Rubinstein L, Harris P, Yoshino T, Doi T, Ohtsu A, Welch J, Takebe N. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488. PMID: 27510411.
      Citations: 4     Fields:    Translation:Humans
    73. Takebe N, Ahmed MM, Vikram B, Bernhard EJ, Zwiebel J, Norman Coleman C, Kunos CA. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Semin Radiat Oncol. 2016 10; 26(4):271-80. PMID: 27619249.
      Citations: 4     Fields:    Translation:Humans
    74. Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8. PMID: 27163943; PMCID: PMC4956531.
      Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
    75. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res. 2016 Oct 01; 22(19):4786-4796. PMID: 27154916; PMCID: PMC5050072.
      Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
    76. Takebe N, Yang SX. Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach. Chin Clin Oncol. 2016 Feb; 5(1):1. PMID: 26932425.
      Citations: 4     Fields:    Translation:HumansCells
    77. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23. PMID: 26598548; PMCID: PMC4722891.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    78. Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122(4):588-597. PMID: 26566079; PMCID: PMC4742409.
      Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
    79. Bando H, Takebe N. Perspectives on research activity in the USA on Cancer Precision Medicine. Jpn J Clin Oncol. 2016 Feb; 46(2):106-10. PMID: 26531706; PMCID: PMC4751220.
      Citations: 3     Fields:    Translation:Humans
    80. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. PMID: 26527777; PMCID: PMC4678179.
      Citations: 264     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    81. Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, Govindharajulu JP, Donohue J, Esposito D, Mapes JP, Kinders RJ, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res. 2016 Feb 15; 22(4):1000-10. PMID: 26446940; PMCID: PMC4755826.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    82. Bando H, Takebe N. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6. PMID: 26423340; PMCID: PMC4635628.
      Citations: 3     Fields:    Translation:Humans
    83. Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54. PMID: 26169613; PMCID: PMC4534527.
      Citations: 204     Fields:    Translation:HumansCTClinical Trials
    84. Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42. PMID: 25971907.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    85. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015 Aug; 12(8):445-64. PMID: 25850553; PMCID: PMC4520755.
      Citations: 635     Fields:    Translation:HumansCells
    86. Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, Mitchell SA, Pavletic SZ, Figg WD, Yao L, Flanders KC, Takebe N, Sarantopoulos S, Booher S, Cowen EW. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1083-90. PMID: 25771402; PMCID: PMC4425991.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    87. Takebe N, McShane L, Conley B. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat Rev Clin Oncol. 2015 Mar; 12(3):132-4. PMID: 25687910.
      Citations: 18     Fields:    Translation:Humans
    88. Nguyen D, Rubinstein L, Takebe N, Miele L, Tomaszewski JE, Ivy P, Doroshow JH, Yang SX. Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 2015 Feb 06; 8:9. PMID: 25653136; PMCID: PMC4343190.
      Citations: 17     Fields:    Translation:HumansCells
    89. Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 01; 20(23):5937-5945. PMID: 25278454; PMCID: PMC4254161.
      Citations: 149     Fields:    Translation:HumansCellsCTClinical Trials
    90. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903. PMID: 24891015; PMCID: PMC4134764.
      Citations: 6     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    91. Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16. PMID: 24788563; PMCID: PMC4281773.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    92. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014; 71-6. PMID: 24857062.
      Citations: 72     Fields:    Translation:Humans
    93. Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, Cassier P, Domont J, Takebe N, Kind M, Coindre JM, Blay JY, Bui B. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov; 24(11):2922-6. PMID: 24170610; PMCID: PMC3811907.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    94. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12. PMID: 24077351; PMCID: PMC3856244.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    95. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014 Feb; 141(2):140-9. PMID: 24076266; PMCID: PMC3982918.
      Citations: 204     Fields:    Translation:HumansAnimalsCells
    96. Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):295-302. PMID: 23860642; PMCID: PMC3895103.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    97. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. PMID: 23553850; PMCID: PMC3674138.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    98. Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Bentzen SM, Okunieff P, Coleman CN, Dicker AP. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24. PMID: 23231975; PMCID: PMC3536642.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    99. Takebe N, Hunsberger S, Yang SX. Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence. Chin J Cancer Res. 2012 Dec; 24(4):257-8. PMID: 23358885; PMCID: PMC3551324.
      Citations: 4     
    100. Trimble EL, Ledermann J, Law K, Miyata T, Imamura CK, Nam BH, Kim YH, Bang YJ, Michaels M, Ardron D, Amano S, Ando Y, Tominaga T, Kurokawa K, Takebe N. International models of investigator-initiated trials: implications for Japan. Ann Oncol. 2012 Dec; 23(12):3151-3155. PMID: 22843420; PMCID: PMC3501232.
      Citations:    Fields:    Translation:Humans
    101. Cerna D, Li H, Flaherty S, Takebe N, Coleman CN, Yoo SS. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem. 2012 Jun 22; 287(26):22408-17. PMID: 22570471; PMCID: PMC3381200.
      Citations: 45     Fields:    Translation:HumansCells
    102. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011 Jun 10; 13(3):211. PMID: 21672282; PMCID: PMC3218933.
      Citations: 107     Fields:    Translation:HumansAnimalsCells
    103. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34. PMID: 21642685; PMCID: PMC3986039.
      Citations: 312     Fields:    Translation:HumansCTClinical Trials
    104. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):481-5. PMID: 21620511; PMCID: PMC3715068.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    105. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15; 17(4):654-66. PMID: 21325294; PMCID: PMC3075808.
      Citations: 471     Fields:    Translation:HumansAnimalsCells
    106. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011 Feb; 8(2):97-106. PMID: 21151206.
      Citations: 468     Fields:    Translation:HumansAnimalsCells
    107. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9. PMID: 21523723; PMCID: PMC3117018.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    108. Harris PJ, Takebe N, Ivy SP. Molecular conversations and the development of the hair follicle and basal cell carcinoma. Cancer Prev Res (Phila). 2010 Oct; 3(10):1217-21. PMID: 20858758; PMCID: PMC2992967.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    109. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15. PMID: 20855820; PMCID: PMC2974341.
      Citations: 99     Fields:    Translation:HumansCellsCTClinical Trials
    110. Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2010 Jul; 2(4):237-50. PMID: 21789137; PMCID: PMC3126020.
      Citations: 140     
    111. Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res. 2010 Jun 15; 16(12):3106-12. PMID: 20530695; PMCID: PMC5207800.
      Citations: 48     Fields:    Translation:HumansCells
    112. Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol. 2010 Mar; 7(3):127-8. PMID: 20190792.
      Citations: 2     Fields:    Translation:Humans
    113. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1079-85. PMID: 20165849; PMCID: PMC2945625.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    114. Minig L, Trimble EL, Birrer MJ, Kim KY, Takebe N, Abrams JS. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol. 2010 Feb; 116(2):177-80. PMID: 19889449.
      Citations:    Fields:    Translation:Humans
    115. Takebe N, Gage F, Cheng X, Lauw MI. Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions. Transfusion. 2009 Sep; 49(9):1911-6. PMID: 19497058.
      Citations: 1     Fields:    Translation:HumansCells
    116. Sausville J, Molinolo AA, Cheng X, Frampton J, Takebe N, Gutkind JS, Feldman RA. RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development. Clin Cancer Res. 2008 Jun 15; 14(12):3948-55. PMID: 18559617.
      Citations: 4     Fields:    Translation:AnimalsCells
    117. Cheng X, Macvittie T, Meisenberg B, Welty E, Farese A, Tadaki D, Takebe N. Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact. Growth Factors. 2007 Jun; 25(3):141-50. PMID: 18049950.
      Citations:    Fields:    Translation:HumansAnimalsCells
    118. Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res. 2007 Sep; 31(9):1165-73. PMID: 17324462.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    119. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, Bauer K, Shaughnessy J, Tricot G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006 Feb; 5(2):457-66. PMID: 16505121.
      Citations: 26     Fields:    Translation:HumansCells
    120. Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72. PMID: 16247422.
      Citations: 5     Fields:    Translation:Humans
    121. Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 2005 Jun 20; 23(18):4089-99. PMID: 15867202.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    122. Inoue Y, Chua K, McClure RF, Jimenez MC, Gocke CD, Badros AZ, Takebe N. Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites. Leuk Res. 2005 Jun; 29(6):715-8. PMID: 15863214.
      Citations: 8     Fields:    Translation:Humans
    123. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8. PMID: 15623606.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    124. Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther. 2004 Dec; 11(12):767-73. PMID: 15359285.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    125. Rapoport AP, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E, Meisenberg B, Mannuel H, Takebe N, Fenton R, Bola?os-Meade J, Heyman M, Gojo I, Ruehle K, Natt S, Ratterree B, Withers T, Sarkodee-Adoo C, Phillips GL, Tricot G. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Nov; 34(10):883-90. PMID: 15517008.
      Citations: 8     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    126. Phillips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J, Fenton R, Filicko J, Grosso D, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Nath R, Reed E, Rapoport AP, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004 Jul; 10(7):473-83. PMID: 15205668.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    127. Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004 Jul; 34(1):69-76. PMID: 15133484.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    128. Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004 Apr; 33(8):781-7. PMID: 14767498.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    129. Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, Bertino JR. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum Gene Ther. 2003 Mar 20; 14(5):435-46. PMID: 12691609.
      Citations: 2     Fields:    Translation:AnimalsCells
    130. Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, H?lscher AH, Danenberg KD, Danenberg PV. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7. PMID: 12538473.
      Citations: 30     Fields:    Translation:HumansCells
    131. Takebe N, Xu LC, MacKenzie KL, Bertino JR, Moore MA. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002 Mar; 9(3):308-20. PMID: 11896448.
      Citations: 2     Fields:    Translation:HumansCells
    132. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002 Feb; 29(4):303-12. PMID: 11896427; PMCID: PMC7091694.
      Citations: 4     Fields:    Translation:Humans
    133. Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001 Dec; 8(12):966-73. PMID: 11781659.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    134. Takebe N, Zhao SC, Adhikari D, Mineishi S, Sadelain M, Hilton J, Colvin M, Banerjee D, Bertino JR. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther. 2001 Jan; 3(1):88-96. PMID: 11162315.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    135. Takebe N, Nakahara S, Zhao SC, Adhikari D, Ural AU, Iwamoto M, Banerjee D, Bertino JR. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors. Cancer Gene Ther. 2000 Jun; 7(6):910-9. PMID: 10880023.
      Citations:    Fields:    Translation:HumansAnimalsCells
    136. Ural AU, Takebe N, Adhikari D, Ercikan-Abali E, Banerjee D, Barakat R, Bertino JR. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol Oncol. 2000 Mar; 76(3):305-10. PMID: 10684701.
      Citations: 1     Fields:    Translation:HumansCells
    137. Banerjee D, Tong Y, Liu-Chen X, Capiaux G, Ercikan-Abali EA, Takebe N, O'Connor OA, Bertino JR. Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Prog Exp Tumor Res. 1999; 36:107-14. PMID: 10386068.
      Citations:    Fields:    Translation:HumansCells
    138. Takebe N, Paredes J, Pino MC, Lownsbury WH, Agosti J, Krown SE. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. J Interferon Cytokine Res. 1998 May; 18(5):321-6. PMID: 9620359.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    139. Mineishi S, Nakahara S, Takebe N, Zhao SC, Banerjee D, Bertino JR. Purine salvage rescue by xanthine-guanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Cancer Gene Ther. 1998 May-Jun; 5(3):144-9. PMID: 9622097.
      Citations:    Fields:    Translation:AnimalsCells
    140. Mineishi S, Nakahara S, Takebe N, Banerjee D, Zhao SC, Bertino JR. Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Ther. 1997 Jun; 4(6):570-6. PMID: 9231073.
      Citations:    Fields:    Translation:AnimalsCells
    141. Inagaki Y, Tsunokawa Y, Takebe N, Nawa H, Nakanishi S, Terada M, Sugimura T. Nucleotide sequences of cDNAs for human papillomavirus type 18 transcripts in HeLa cells. J Virol. 1988 May; 62(5):1640-6. PMID: 2833614; PMCID: PMC253192.
      Citations: 24     Fields:    Translation:HumansCells
    Takebe's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (532)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _